Diego A. Díaz García/X
Apr 15, 2025, 11:52
Diego A. Díaz García: Updates on the treatment of EGFR-mutant NSCLC
Diego A. Díaz García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared a post on X:
“Updates on the treatment of EGFR-mutant NSCLC.
Third-gen TKIs are standard first-line. Combos with chemo or amivantamab extend PFS (and now OS in Mariposa ph3 trial). Resistance remains a challenge—tailored strategies are key.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 18, 2025, 07:34
Apr 18, 2025, 07:22
Apr 18, 2025, 07:02
Apr 18, 2025, 06:58
Apr 18, 2025, 06:50
Apr 18, 2025, 03:14
Apr 18, 2025, 03:06